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Effective resolution of inflammation is orchestrated through a 
complex array of mediators and cellular mechanisms. Increas-
ing evidence indicates that the seeds of this resolution phase 
exist even at the height of inflammation. Regulatory T cells 
(T reg cells) are potent suppressors of immune responses and 
are considered pivotal in resolving inflammation and auto-
immunity (Miyara et al., 2011). T reg cells occur in increased 
numbers in a wide variety of inflammatory diseases such as 
the synovium of patients with rheumatoid arthritis (RA; Cao 
et al., 2004; van Amelsfort et al., 2004), although one group 
found no difference in the frequency of T reg cells between 
the inflamed synovial fluid and peripheral blood (Nie et al., 
2013). There is substantial controversy as to whether these 
T reg cells are fully suppressive, and the precise mechanisms 
that modulate T reg cell number and function during inflam-
mation remain unclear. We and others have shown that T reg 
cells from RA patients are defective in their ability to suppress 
proinflammatory cytokines (Ehrenstein et al., 2004; Valencia 
et al., 2006; Flores-Borja et al., 2008; Zanin-Zhorov et al., 
2010; Cribbs et al., 2014).
To understand the interrelationship between inflamma-
tion and T reg cell number and function, significant atten-
tion has been paid to the actions of TNF, which is known to 
play a pivotal role in several inflammatory disorders including 
RA. However, recent evidence studying this cytokine’s im-
pact on T reg cells has led to contradictory and controversial 
results. Although some investigators have shown that TNF 
can impair T reg cell function (Valencia et al., 2006; Nagar 
et al., 2010; Nie et al., 2013), others have found that TNF 
enhances their capacity to suppress via its interaction with 
TNF-RII expressed by T reg cells (Grinberg-Bleyer et al., 2010; 
Kleijwegt et al., 2010; Chen et al., 2013; Chopra et al., 2013; 
Zaragoza et al., 2016).
Anti-TNF therapy has revolutionized the therapy of a 
variety of inflammatory diseases including RA. We have pre-
viously shown that adalimumab, an anti-TNF antibody, but 
not etanercept, a soluble TNF receptor, increased T reg cell 
numbers in patients with RA and that these T reg cells were 
capable of suppressing the highly inflammatory cytokine 
IL-17 (McGovern et al., 2012). Our data implied that TNF 
compromised the potency of T reg cell suppression in RA, 
which was reversed by therapeutic TNF blockade. However, 
it was unclear why etanercept, which is as equally effective as 
adalimumab in the treatment of RA, lacked T reg cell mod-
ulatory properties. Here, we reveal that adalimumab, but not 
etanercept, binds to membrane TNF expressed by RA mono-
cytes and promotes T reg cell expansion through enhanced 
TNF-RII–mediated IL-2/STAT5 signaling.
RES ULTS
Adalimumab increased functionally suppressive T reg cells 
in PBMCs from RA patients but not healthy controls
We have previously shown that RA patients receiving adali-
mumab but not etanercept therapy have increased peripheral 
CD4+ T reg cells (McGovern et al., 2012). To elucidate the 
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underlying mechanisms and explain the differing effects of 
these two anti-TNF agents, we established an in vitro model 
avoiding the use of anti-CD3 that can artificially modulate 
Foxp3 expression (Tran et al., 2007; Sakaguchi et al., 2010). 
PBMCs from RA patients or healthy controls were cultured 
for 3 d with either adalimumab or etanercept. Adalimumab 
(or its Fab′2 fragment) but not etanercept (or an isotype con-
trol) increased the percentage and the absolute number of 
CD4+Foxp3+ T reg cells in PBMCs from RA patients (Fig. 1, 
A and B). Of note, adalimumab had the same effect on T reg 
cell enrichment in PBMCs from RA patients treated with dis-
ease-modifying antirheumatic drugs compared with PBMCs 
from untreated patients. In contrast, the number of  T reg cells 
in PBMCs from healthy individuals was unaffected by adali-
mumab or etanercept (Fig. 1, A and B). Without the addition 
of adalimumab, the number of T reg cells was reduced over 
the course of the culture. We noted that the effect of adali-
mumab was dose dependent, with the optimal concentration 
at 10 µg/ml (Fig. 1 C) corresponding to serum concentra-
tions found in patients responding to adalimumab (Bartelds 
et al., 2007). Lower concentrations in the range of 1 µg/ml 
were associated with clinical nonresponsiveness (Bartelds et 
al., 2007) and did not increase T reg cells (Fig. 1 C), whereas 
higher concentrations abrogated this effect of adalimumab.
We have demonstrated that adalimumab therapy led to 
the generation of functional T reg cells equipped to suppress 
Th17 cells in patients treated with this anti-TNF therapy 
in vivo (McGovern et al., 2012). Therefore, we examined 
RORC expression in CD4+ T cells from RA PBMCs ex-
posed to adalimumab. The number of CD4+RORC+ T cells 
was significantly reduced in RA PBMCs after culture with 
adalimumab (Fig.  1 D), matching our in vivo observations 
(McGovern et al., 2012). This decrease in the CD4+RORC+ 
subset together with the rise in T reg cell number led to a 
fivefold increase in the ratio of T reg cells to CD4+RORC+ 
T cells (Fig.  1 E). The reduction in CD4+RORC+ T cells 
driven by adalimumab was reflected by a decrease in Th17 
cells (Fig. 1 F). To determine whether these T reg cells gen-
erated by adalimumab in vitro were functionally suppressive, 
we established classical suppression assays using untreated re-
sponder T cells and monocytes together with T reg cells (CD4+ 
CD25+CD127−) isolated from the cultures described in the 
previous paragraph. T reg cells purified from RA PBMCs ex-
posed to adalimumab, but not etanercept, significantly sup-
pressed IL-17 and IFN-γ production (Fig. 1 G). Consistent 
with previous findings (Ehrenstein et al., 2004; Valencia et al., 
2006; Flores-Borja et al., 2008; Zanin-Zhorov et al., 2010; 
Cribbs et al., 2014), unmanipulated RA T reg cells were defec-
tive with respect to regulating IFN-γ production (Fig. 1 G).
T reg cells and monocytes were required for the 
adalimumab-induced T reg cell expansion
To examine which cell subsets were targeted by adalimumab 
to mediate T reg cell expansion, we first depleted T reg cells 
or monocytes from PBMCs. Removal of either monocytes or 
T reg cells from PBMCs from RA patients abolished the in-
crease in T reg cells upon addition of adalimumab (Fig. 2 A). 
When responder T cells or T reg cells from RA patients were 
stimulated with adalimumab in the presence of monocytes, 
only the latter responded to adalimumab with respect to in-
creased T reg cells compared with unstimulated cultures at 
day 3 (Fig. 2 B). In keeping with the data in Fig. 1, etaner-
cept had no effect on Foxp3 expression (Fig. 2 B). There was 
some reduction in Foxp3 expression over the course of the 
culture, though this was least when adalimumab was pres-
ent. Adalimumab but not etanercept significantly promoted 
the proliferation of T reg cells but had no effect on CD4+-
Foxp3− responder T cells (Fig. 2 C). There was no difference 
in T reg or monocyte cell death between the different treat-
ment groups (Fig. 2 D).
Adalimumab bound to membrane TNF 
expressed by RA monocytes
These results led us to explore the molecular basis for the 
interaction between monocytes and T reg cells. Having iden-
tified the two cell types required for adalimumab to expand 
T reg cells, we examined the binding of adalimumab to puri-
fied T reg cells and monocytes. Neither biotinylated adalim-
umab nor etanercept bound to T reg cells from RA patients 
or healthy controls (Fig. 3 A). In contrast, adalimumab but 
not etanercept bound to monocytes from RA patients but 
not healthy controls (Fig. 3 B). Unexpectedly, we noted that 
the monocytes that had bound the biotinylated adalimumab 
increased their membrane TNF expression (Fig.  3 C). Re-
peating this experiment with adalimumab that had not been 
biotinylated, we confirmed that membrane TNF expression 
was elevated after addition of adalimumab to purified RA 
monocytes. Adalimumab did not have any effect on monocyte 
TNF expression in healthy controls (Fig. 3 D). These findings 
paralleled in vivo observations from patients responding to 
adalimumab therapy, where monocytes from adalimumab re-
sponders had increased TNF expression compared with RA 
patients treated with methotrexate or etanercept (Fig. 3 E). 
Quantitative ImageStream technology confirmed the co-
expression of membrane TNF and adalimumab (Fig.  3  F). 
Moreover, there was significant colocalization between adali-
mumab and membrane TNF on RA monocytes as assessed by 
the bright detailed similarity (BDS) index (Fig. 3 G).
Adalimumab promoted binding between monocyte 
membrane TNF and TNF-RII expressed by T reg cells
We next investigated whether adalimumab expands T reg cells 
through the interaction between monocyte membrane TNF 
and T reg cell TNF-RII. ImageStream technology has the po-
tential to both image and quantify many thousands of inter-
actions between monocytes and T reg cells. Monocytes and 
T reg cells were stained for TNF-RII and membrane TNF 
after culture with biotinylated adalimumab or etanercept. 
Adalimumab but not etanercept promoted T reg cell–mono-
cyte conjugate formation after a 30-min incubation (Fig. 4 A). 
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Figure 1. Adalimumab increased the number of functionally suppressive T reg cells in PBMCs from RA patients but not healthy con-
trols. (A, B, D, and E) 2 × 105 PBMCs from untreated or disease-modifying antirheumatic drug (DMA RD)–treated RA patients and healthy controls (HC) 
were cultured with 10 µg/ml adalimumab, adalimumab F(ab’)2 (n = 11), etanercept, or isotype control for 3 d. (A and B) Representative flow cytometry and 
cumulative data indicating the percentage and absolute number of CD4+FoxP3+ from RA patients divided into untreated (n = 13), on disease-modifying 
antirheumatic drug (n = 13), and healthy controls (n = 8) at time zero (T0) and at day 3 of the culture. (C) Adalimumab dose–response curve from RA 
PBMCs exposed to increasing concentrations of adalimumab for 3 d. Cumulative data depict percentage of CD4+FoxP3+ T reg cells (n = 7). (D) Percentage 
and absolute number of CD4+RORC+ cells in the cultures at day 3 (n = 10). (E) The ratio of CD4+FoxP3+/CD4+RORC+ in the PBMC cultures from RA patients 
at day 3 (n = 10). (F) After exposure to either anti-TNF agent for 3 d, CD4+ T cells were stained for IL-17 cytokine production. Representative flow cytometry 
shows IL-17 production from CD4+ in RA (n = 18). (G) Classical T reg cell suppression assay: adalimumab- or etanercept-treated RA T reg cells were purified 
(CD4+CD25+CD127−) and co-cultured for 5 d with monocytes and untreated responder T cells (CD4+CD25−CD127+) at a 1:3 ratio in the presence of 1 µg/
ml anti-CD3/CD28. Cumulative data indicate percentage of suppression of IL-17 (n = 6) and IFN-γ (n = 6) production. Data in A and B were obtained from 
five experimental repeats. C was obtained from two experimental repeats. D, E, and G were obtained from three experimental repeats. F is representative 
of six independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 using Kruskal-Wallis with Dunn’s post-hoc analysis. Error bars represent mean ± SE.
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Figure 2. T reg cells and monocytes were required for the adalimumab-driven T reg cell expansion. (A) PBMCs from RA patients were sorted into 
three populations: whole PBMCs, PBMCs depleted of CD14+ monocytes, and PBMCs depleted of CD4+CD25+CD127− T reg cells and stimulated with adalim-
umab, etanercept, or an isotype control for 3 d. The percentage of CD4+Foxp3+ T cells is shown (n = 4). (B) T reg cells or responder T cells (Tresp) and CD14+ 
monocytes (MC) from RA patients were isolated by FACS before being co-cultured in the presence of adalimumab or etanercept for 3 d. The cumulative data 
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The majority of these conjugates coexpressed adalimumab 
and TNF-RII (Fig. 4 B). Both membrane TNF and adalim-
umab were present in the synapse between monocytes and 
T reg cells as defined by the valley mask (Fig. 4 C; Ahmed et 
al., 2009). Colocalization of membrane TNF and TNF-RII 
in the T reg cell–monocyte conjugates was demonstrated by 
analysis of the BDS index using ImageStream (Fig. 4 D).
TNF-RII stimulation triggered expansion 
of the T reg cell subset
Blockade of TNF-RII abolished the increase in T reg cells 
driven by adalimumab, confirming the pivotal role of the 
TNF–TNF-RII interaction between monocytes and T reg 
cells (Fig. 5 A). TNF-RII expression on RA T reg cells was 
enhanced in the presence of adalimumab in vitro (Fig. 5 B). 
This effect was mirrored in vivo in RA patients responding to 
adalimumab (Fig. 5 C). No increase in TNF-RII expression 
occurred in responder T cells from patients treated with and 
responding to adalimumab (Fig. 5 C). An increase in the po-
larization of TNF-RII distribution was detected on the T reg 
cell surface in the presence of adalimumab (Fig. 5 D).
IL-2/STAT5 signaling was required for adalimumab-
driven T reg cell expansion
TNF-RII promotes the production of IL-2 (McKarns and 
Schwartz, 2008; Miller et al., 2015), which has a pivotal role in 
the generation, homeostasis, and in vivo proliferation of  T reg 
cells (Cheng et al., 2011). Moreover, T reg cells from patients 
with autoimmune disease can produce increased amounts of 
IL-2 compared with healthy T reg cells (Carbone et al., 2014). 
Therefore, we examined IL-2 secretion by purified T reg cells 
from RA patients cultured in the presence of monocytes. 
Adalimumab increased the production of IL-2 by purified 
T reg cells from RA patients but not healthy controls (Fig. 6, 
A and B). Moreover, TNF-RII blockade abrogated the en-
hanced IL-2 production triggered by adalimumab (Fig. 6 A). 
IL-2 production was increased in those purified T reg cells 
that maintained high expression of Foxp3, though low Foxp3 
cells also produced this cytokine.
IL-2 signaling in human T reg cells results in the phos-
phorylation of STAT5 (Zorn et al., 2006). TNF-RII drives 
STAT5 phosphorylation in synergy with IL-2 in mouse 
T reg cells (Chen et al., 2007). Therefore, we examined 
whether adalimumab affected T reg cell STAT5 signaling. 
Adalimumab increased STAT5 phosphorylation in RA T reg 
cells (Fig. 6 C) and Foxp3 expression (Fig. 6 D) to a similar 
degree as direct stimulation of TNF-RII. Blockade of IL-2 
and TNF-RII alone or together abrogated the increase of 
STAT5 phosphorylation (Fig. 6 E) and T reg cell expansion 
(Fig. 6 F) stimulated by adalimumab. Addition of a STAT5 in-
hibitor alone or together with anti–IL-2 and anti–TNF-RII 
antagonist prevented the T reg cell enrichment by adalimumab 
(Fig. 6 F), indicating that T reg cell expansion was dependent 
on the STAT5 pathway. Incubation of PBMCs with etaner-
cept did not increase STAT5 phosphorylation (Fig. 6 E).
DIS CUS SION
The importance of TNF has been clearly demonstrated 
through therapeutic blockade in patients with a variety of 
inflammatory disorders. However, its role in modulating the 
function of T reg cells has remained controversial because of 
several apparently contradictory findings in mice and humans 
(Valencia et al., 2006; Grinberg-Bleyer et al., 2010; Kleijwegt 
et al., 2010; Nagar et al., 2010; Chen et al., 2013; Chopra et 
al., 2013; Nie et al., 2013; Zaragoza et al., 2016). Here, we re-
veal how anti-TNF antibodies can not only preserve, but also 
enhance the regulatory properties of this proinflammatory 
cytokine in patients with chronic inflammation.
Through a series of linked observations, we have demon-
strated that adalimumab binds to membrane TNF on mono-
cytes, enhancing both the expression of membrane TNF and 
its binding to TNF-RII on T reg cells. We show that TNF-
RII expressed by T reg cells from RA patients drives the ex-
pansion of T reg cells able to suppress Th17 cells via STAT5, 
which is consistent with previous data from mouse and human 
studies implicating TNF-RII as a potent enhancer of T reg 
cell function (Grinberg-Bleyer et al., 2010; Chen et al., 2013; 
Beilhack et al., 2014; McCann et al., 2014). The fact that 
T reg cell suppression was restored in RA patients after anti- 
TNF therapy (Ehrenstein et al., 2004) appeared to support 
the notion that TNF was detrimental to T reg cell function. 
However, the data presented here implicate an alternative in-
terpretation, specifically that therapeutic anti-TNF antibodies 
paradoxically promote T reg cell TNF-RII signaling to drive 
their expansion. These results highlight how a treatment that 
targets a pivotal inflammatory cytokine not only preserves, 
but actually boosts the proresolution forces driven by that 
pathway, thereby highlighting a novel therapeutic paradigm.
We have previously published that T reg cells endowed 
with the ability to suppress Th17 cell responses are increased 
in patients responding to adalimumab therapy (McGovern et 
al., 2012). We have now established an in vitro model of these 
in vivo observations, thereby enabling the dissection of the 
underlying mechanisms. Adalimumab bound to monocytes 
and representative flow cytometry plot indicate the percentage of CD4+FoxP3+ on day 0 and in each set of co-cultures on day 3 (n = 4). (C) Ki67 staining 
gated on CD4+FoxP3+ and CD4+FoxP3− in PBMCs from RA patients (n = 8) exposed for 3 d to either adalimumab or etanercept. MFI, mean fluorescence 
intensity. (D) The cumulative data of active Caspase 3 expression on CD4+FoxP3+ T reg cells or monocytes from RA patients (n = 14) and healthy controls 
(HC; n = 8) after culturing PBMCs for 3 d with either adalimumab or etanercept. The data in A and B were obtained from two experimental repeats, and 
data in C and D were obtained from four experimental repeats. **, P < 0.01; ***, P < 0.001 using Kruskal-Wallis tests with Dunn’s post-hoc analysis. Error 
bars represent mean ± SE.
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rather than T reg cells and increased the expression of mono-
cyte membrane TNF. Monocytes are known to be activated 
in RA patients (Evans et al., 2009; McGovern et al., 2012) and 
express more membrane TNF compared with their healthy 
counterparts (Meusch et al., 2009). Membrane-bound TNF 
on monocytes has been shown to be superior to soluble 
TNF in activating TNF-RII (Kleijwegt et al., 2010; Rauert 
et al., 2010). It has been reported that infliximab, a chime-
ric anti-TNF antibody, bound strongly to monocytes but not 
CD4+ T cells (Coulthard et al., 2012), which is consistent 
with our results using the purely human anti-TNF antibody 
adalimumab. However, our data indicate that adalimumab not 
only passively detects membrane TNF, but actually increases 
its expression in RA monocytes. The mechanism that may 
underlie this surprising result is unclear, but one possibility is 
that adalimumab stabilizes membrane TNF at the cell surface 
and prevents recycling or cleavage to soluble TNF.
The increase in monocyte membrane TNF driven by 
adalimumab, which occurred both in vitro and in vivo, led 
not only to enhancement of T reg cell TNF-RII expression, 
but also its binding to membrane TNF. Recent structural 
comparisons of TNF-adalimumab Fab and TNF–TNF-RII 
reveal that only 7 of 21 TNF residues involved in the TNF-
RII binding also participate in contacting the adalimumab 
Fab molecule (Hu et al., 2013). These data raise the possibility 
that adalimumab and TNF-RII present at the conjugate syn-
apse may not block each other’s binding by interacting with 
different parts of the same or another membrane TNF mole-
cule in close proximity. Notwithstanding these observations, 
crystallographic studies of TNF–anti-TNF complexes are de-
rived from the interaction between soluble molecules, mak-
ing it difficult to draw precise conclusions about the binding 
between membrane-bound molecules. Our data indicate that 
the T reg cell expansion driven by adalimumab occurs in a 
relatively narrow concentration range, which closely relates 
to therapeutic efficacy (Bartelds et al., 2007). It is tempting 
to speculate that the spatiotemporal geometry that permits 
adalimumab to enhance TNF–TNF-RII interactions is par-
ticularly sensitive to changes in adalimumab concentration. 
An intermediate adalimumab concentration may block some 
but not all membrane TNF domains, allowing for not only 
cross-linking of TNF trimers, but also enough unoccupied 
TNF domains to bind TNF-RII. The polarization of TNF-
RII on T reg cells induced by adalimumab is consistent with 
the formation of TNF–TNF-RII aggregates, which are re-
quired for the initiation of TNF-RII intracellular signaling 
(Mukai et al., 2010). TNF-RII expression on T reg cells has 
been linked with enhanced suppressive capacity (Chen et al., 
2007), which agrees with our observations that adalimumab- 
expanded T reg cells can control IL-17 production unlike 
their healthy counterparts (McGovern et al., 2012).
Etanercept bound weakly to RA monocytes and did 
not result in the cascade of events including TNF-RII po-
larization at the surface of T reg cells and STAT5 signaling 
that led to Foxp3 expansion. Several studies have examined 
the distinct actions of anti-TNF antibodies and etanercept, 
initially prompted by the divergent efficacy of these two 
classes of TNF antagonists in the treatment of Crohn’s dis-
ease (Patil et al., 2013; Peake et al., 2013). Differences in their 
half-life and effects on membrane TNF have been suggested, 
but no definitive explanation has been obtained (Horiuchi 
et al., 2010). Our data favor the interpretation that the key 
distinction between these two types of TNF inhibitors re-
sides in their differing avidity for monocyte membrane TNF 
expressed by monocytes from RA patients. A further advan-
tage of establishing the in vitro model is that it allows for a 
comparison of the effects of adalimumab on healthy controls 
who would not receive anti-TNF therapy. Monocytes from 
healthy controls expressed minimal levels of membrane TNF 
(Meusch et al., 2009), which could account for the lack of 
binding of adalimumab. These findings reinforce not only 
the notion that the inflammatory milieu is important in pro-
moting T reg cell expansion, but also that understanding how 
inflammation is resolved requires the analysis of patient as 
well as healthy samples.
The up-regulation of Foxp3 by adalimumab was reliant 
upon low levels of IL-2 production and subsequently STAT5 
activation. The dependence of T reg cells on IL-2 is well es-
tablished (Cheng et al., 2011; Zaragoza et al., 2016). Human 
T reg cells are known to be highly sensitive to low doses of 
Figure 3. Adalimumab bound to membrane TNF on RA monocytes. (A and B) Adalimumab and etanercept were biotinylated and added to purified 
CD4+CD25+CD127− T reg cells (A) or purified CD14+ monocytes (B) from RA patients and healthy controls (HC) for 30 min. Bound adalimumab and etaner-
cept were detected using an APC-streptavidin secondary antibody. Representative plots and cumulative data depict percentage of binding of each anti-TNF 
agent to T reg cells from RA patients (n = 12) and healthy individuals (n = 10; A) and to monocytes (number of RA = 8; number of healthy controls = 10; B). 
(C) The bars depict membrane TNF (mTNF) mean fluorescence intensity (MFI) on RA monocytes either bound (Bio+ve) or unbound (Bio−ve) by biotinylated 
adalimumab for 30 min (n = 11). (D) Membrane TNF expression on purified CD14+ monocytes from RA patients (n = 28) and healthy controls (n = 8) ex-
posed for 24 h to adalimumab, etanercept, or isotype control. (E) Ex vivo expression of monocyte membrane TNF from RA patients with active disease (n = 
23), adalimumab responders (n = 19), etanercept responders (n = 15), and healthy individuals (n = 11). (F) Purified monocytes were stained for CD14+ and 
membrane TNF after co-culture with biotinylated adalimumab or etanercept for 30 min. ImageStream cumulative data indicate coexpression of membrane 
TNF and either adalimumab or etanercept on monocytes. Unstimulated are shown as background (n = 5). (G) The ImageStream gallery includes brightfield 
(BF), CD14, membrane TNF, biotinylated adalimumab, and etanercept (anti-TNF), composite merged images. The bars depict the BDS index (colocalization) of 
adalimumab and etanercept with membrane TNF occurring at the surface of CD14+ monocytes (n = 5). Data in A–C were obtained from three experimental 
repeats. Data in D and E were from six and F and G were from two experimental repeats. **, P < 0.01; ***, P < 0.001 using Kruskal-Wallis (A–D, F, and G) or 
Friedman tests (E) with Dunn’s post-hoc analysis. Error bars represent mean ± SE.
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IL-2, some 100-fold less than responder T cells (Yu et al., 
2015). Moreover, similarly low concentrations of IL-2 have 
been recently shown to boost the effects of TNF and expand 
human T reg cells (Zaragoza et al., 2016). TNF-RII is able to 
increase the sensitivity of IL-2 signaling, thereby amplifying 
the impact of small changes in IL-2 production (Chen et al., 
2007; Mahmud et al., 2014). We found that adalimumab stim-
ulated IL-2 production consistent with a recent study indicat-
ing that IL-2 transcription was directly triggered by TNF-RII 
(Miller et al., 2015). The defective regulation of IL-2 produc-
Figure 4. Adalimumab promoted the in-
teraction between monocyte membrane 
TNF and TNF-RII expressed by T reg cells. 
(A) Purified T reg cells and monocytes from 
RA patients were treated with biotinylated 
adalimumab or etanercept for 30 min. Rep-
resentative imaging flow cytometry (Image-
Stream) and cumulative data of T reg cell 
(Treg)–monocyte conjugate formation in the 
presence of either anti-TNF agent. (B) Repre-
sentative ImageStream plots and cumulative 
data reveal the percentage of conjugates co-
expressing either anti-TNF agent or TNF-RII. 
(C) Cumulative data depicting membrane TNF 
(mTNF) and either adalimumab or etanercept 
intensity in the valley mask of the conjugate 
synapse. (A–C) n = 5. Data were obtained from 
three experimental repeats. **, P < 0.01; ***, P 
< 0.001 using Kruskal-Wallis tests with Dunn’s 
post-hoc analysis. Error bars represent mean 
± SE. (D) Representative merged images of 
CD4+ T reg cell, CD14+ monocyte, membrane 
TNF, TNF-RII, and anti-TNF. The BDS index (co-
localization) of membrane TNF and TNF-RII at 
the conjugate interface in monocyte–T reg cell 
cultures treated with or without adalimumab 
is shown. Data are representative of three ex-
perimental repeats.
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tion reported in autoimmune disease (Carbone et al., 2014) 
may enhance susceptibility to T reg cell expansion driven by 
adalimumab. Upon addition of adalimumab, IL-2 production 
was increased by those purified T reg cells that maintained 
a high expression of Foxp3, but low Foxp3 T cells also in-
creased their production of IL-2. The provenance of these 
IL-2–secreting Foxp3 low T cells is unclear but could derive 
either from T reg cells that had lost Foxp3 expression over 
the course of the culture or from an expansion of responder 
(conventional) T cells contaminating the FACS-purified 
T reg cells. Indeed, in vivo, it is possible that responder T cells 
are the main source of the IL-2 driving T reg cell expansion 
in response to adalimumab. TNF-RII expression tended to 
be highest on T reg cells, and its expression was increased by 
adalimumab in contrast to the unaltered TNF-RII expression 
on responder T cells. However, a proportion of responder 
T cells express TNF-RII at levels comparable to T reg cells, 
and these could also be triggered by monocyte membrane 
TNF to produce IL-2 in the same manner as T reg cells.
Anti-TNF antibodies appear to be the first example of 
a therapeutic cytokine inhibitor that paradoxically promotes 
the regulatory functions of its target. Anti-TNF antibodies 
Figure 5. Adalimumab-enhanced TNF-RII 
expression and polarization on the surface 
of T reg cells. (A) 10 µg/ml anti–TNF-RII an-
tagonist antibody was added to PBMCs from 
RA patients treated with adalimumab for 3 d. 
Representative flow cytometry and cumulative 
data indicate percentage of CD4+FoxP3+ T reg 
cells (n = 10). (B) Purified CD4+CD25+CD127− 
T reg cells from RA patients were cultured with 
purified monocytes and treated with either 
adalimumab or isotype control for 24  h. The 
representative flow cytometry plots and cu-
mulative data show expression of TNF-RII on 
FoxP3+ T reg cells and those purified T reg cells 
that had low Foxp3 expression (n = 21). MFI, 
mean fluorescence intensity. (C) Ex vivo TNF-
RII expression on CD4+FoxP3+ T reg cells and 
CD4+FoxP3− responder T cells from RA patients 
with active disease (n = 29), patients respond-
ing to adalimumab (n = 27) or etanercept 
therapy (n = 13), and healthy individuals (n = 
8). (D) Adalimumab or etanercept was added 
to purified RA T reg cells cultured for 24  h 
in the presence of monocytes. Samples were 
analyzed using ImageStream after staining 
for CD4+ T reg cells (red) and TNF-RII (yellow). 
The representative composite image shows 
polarized TNF-RII distribution on the surface 
of T reg cells. The cumulative data depict the 
polarity index of TNF-RII on T reg cells (n = 6). 
Data in A was obtained from three experimen-
tal repeats, B and C were obtained from six, 
and D was obtained from two experimental 
repeats. *, P < 0.05; **, P < 0.01; ***, P < 0.001 
using Kruskal-Wallis (A, B, and D) or Friedman 
tests (C) with Dunn’s post-hoc analysis. Error 
bars represent mean ± SE.
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block the proinflammatory soluble TNF while appearing to 
augment the immunosuppressive properties of membrane 
TNF. Future studies will need to examine how these two op-
posing effects of TNF can be individually targeted to resolve 
inflammation and promote tolerance.
MAT ERI ALS AND MET HODS
Patient population
We recruited patients with active RA, whose diagnosis ful-
filled the American College of Rheumatology 1987 revised 
classification criteria for RA (Arnett et al., 1988), and healthy 
Figure 6. Adalimumab T reg cell expansion was driven by IL-2/STAT5 signaling. (A) Purified CD4+CD25+CD127− T reg cells from patients with RA 
or healthy controls (HC) were co-cultured for 72 h with their autologous CD14+ monocytes and adalimumab with or without an anti–TNF-RII antagonist. 
Representative FACS plots (RA only) and cumulative data depicting CD4+FoxP3+ T reg cell IL-2 production in RA (n = 11) and healthy individuals (n = 5) 
are shown. (B) IL-2 production assayed by ELI SA from purified T reg cells and monocytes from RA patients after 3-d exposure to adalimumab (n = 22) and 
healthy controls (n = 13). (C and D) RA PBMCs were exposed for 3 d either to adalimumab or an anti–TNF-RII agonist. Representative histograms and bars 
show phosphor-STAT5 (p-STAT5) expression on CD4+FoxP3+ T reg cells (n = 9; C) and percentage of CD4+FoxP3+ T reg cells (n = 9; D). MFI, mean fluorescence 
intensity. (E) T reg cell phosphor-STAT5 expression in RA PBMCs after blockade of IL-2, TNF-RII, and STAT5 inhibition, either alone or in combination, in the 
presence of adalimumab (n = 9) or etanercept (n = 5). (F) Frequency of FoxP3 T reg cells in RA PBMCs using the same conditions as in E. Data were obtained 
from three experimental repeats. **, P < 0.01; ***, P < 0.001 using Kruskal-Wallis test with Dunn’s post-hoc analysis.
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volunteers. The University College London Hospital Ethics 
Committee approved the study. Patients were untreated or 
receiving methotrexate, sulfalsalazine, hydroxychloroquine, 
or leflunomide and not receiving prednisolone doses >7.5 
mg/d, with their Disease Activity Score (DAS28; Prevoo et 
al., 1995) >5.1 and their C-reactive protein levels >5 mg/
liter. Patients were designated as responding to anti-TNF 
therapy if they had a reduction in their DAS28 score ≥1.2 
and a C-reactive protein <5 mg/liter.
Antibodies and inhibitors
The following antibodies were used: Alexa Fluor 700–con-
jugated CD4 (RPA-TA; BD), allophycocyanin (APC)-Cy7–
conjugated CD25 (M-A251; BD), PE-Cy5 –conjugated 
CD127 (eBioRDR5; eBioscience), Pacific blue–conjugated 
CD14 (M5E2; BD), FITC-conjugated Ki67 (35 Ki-67; BD), 
PE-conjugated RORγτ (AFK JS-9; eBioscience), Alexa Fluor 
647–conjugated FoxP3 (PCH101; eBioscience), PE-con-
jugated FoxP3 (236A/E; eBioscience), FITC-conjugated 
membrane TNF (FAB210F; R&D Systems), PE-conjugated 
TNF-RII (22235; R&D Systems), PE-conjugated STAT5 
(PY694; BD), FITC-conjugated active Caspase 3 (C92-605; 
BD), FITC-conjugated IL-2 (MQ1-17H12; eBioscience), 
Alexa Fluor 647–conjugated Il-17A (BL168; BioLegend), 
PE-Cy7–conjugated IFN-γ (B27; BD), soluble anti-CD3 
(HIT-3a; eBioscience), anti-CD28 (CD28.2; eBioscience), 
anti–TNF-RII antagonist (22221; R&D Systems), anti–
TNF-RII agonist (MR2-1; Hycult Biotech), and anti–IL-2 
neutralizing mAb (MQ1-17H12; BD). STAT5 inhibitor 
N′([4-oxo-4H-chromen-3-yl]methylene) nicotinohydrazide 
(EMD Millipore) was also used. Of relevance, FITC-con-
jugated membrane TNF (FAB210F; R&D Systems) does 
not interfere with membrane TNF’s binding to TNF-RII 
(Gerspach et al., 2000).
Anti-TNF agents
Adalimumab or etanercept was added at a final concentration 
of 10 µg/ml (except for Fig. 1 C, where a range of concen-
trations was used) to PBMCs or co-cultures of purified T reg 
cell and monocyte cultures for 3 d.
Cell purification
Ficoll-Paque (GE Healthcare) was used to isolate PBMCs. 
Specific cell populations were purified by flow cy-
tometry (Aria; BD). The gating strategy for T reg cell 
isolation and depletion and the resulting purities ob-
tained are shown in Fig. S1.
Depletion assay
Whole PBMCs or PBMCs depleted of CD4+CD25+CD127− 
(T reg cell) or CD14+ (monocyte) were purified using flow 
cytometry. These populations were cultured at 3 × 105 cells 
per well in 96-well U-bottomed plates (Thermo Fisher Sci-
entific) with adalimumab, etanercept, or isotype control at a 
concentration of 10 µg/ml for 3 d.
Flow cytometric analysis and soluble cytokine detection
Cell surface and intracellular staining were performed in 
accordance with the manufacturers’ instructions. A FoxP3 
staining buffer set (eBioscience) was used for all intracellu-
lar staining. The secretion of IL-17A, IFN-γ, and IL-2 was 
determined by flow cytometry after 4-h stimulation with 
4 µg/ml phorbol myristate acetate, 1 µg/ml ionomycin, and 
2 µg/ml Golgi Stop (BD).
Preparation of Fab′2 fragment
Fab′2 fragments of adalimumab were prepared with the 
Pierce Fab′2 Micro kit (Thermo Fisher Scientific).
IL-2 ELI SA
IL-2 production by purified monocytes and T reg cell cul-
tures was determined according to human IL-2 ELI SA 
(Ready-SET-Go; eBioscience).
Suppression assay
CD4+CD25+CD127− (T reg cells) were isolated by FACS 
(Aria; BD) from PBMCs cultured with adalimumab or etaner-
cept for 3 d. A classical co-culture suppression assay was then 
performed by co-culturing these anti-TNF–treated T reg 
cells with freshly purified untreated autologous responder T 
cells at a 1:3 ratio in the presence of monocytes and 1 µg/ml 
soluble anti-CD3/CD28 for 5 d. IL-17 and IFN-γ produc-
tion were measured by flow cytometry after a 4-h stimulation 
with 4 µg/ml phorbol myristate acetate, 1 µg/ml ionomycin, 
and 2 µg/ml Golgi Stop. The percentage of suppression of 
IL-17 and IFN-γ was calculated using the following formula: 
percentage of suppression = (Tresp + MC) − (Tresp + MC+ 
Treg) × 100 (Tresp + MC), where Tresp is responder T cells, 
MC is monocytes, and Treg is T reg cells.
Biotinylation binding assay
Biotinylation of adalimumab and etanercept was performed 
in accordance with Thermo Fisher Scientific’s instructions 
for the EZ-Link NHS-PEO Solid-Phase Biotinylation kit. 
Biotinylated adalimumab, etanercept, or human IgG1 isotype 
control was added to purified T reg cells or monocytes from 
RA patients for 30 min before staining for lineage markers 
CD4, CD25, CD14, TNF-RII, and membrane TNF. Cells 
were then resuspended in APC-conjugated streptavidin for 
30 min before acquisition on FACS.
ImageStream analysis
Sorted T reg cells and monocytes were cultured with bioti-
nylated adalimumab or etanercept at 37°C for the time speci-
fied. The cells were then stained with CD4, CD14, membrane 
TNF, TNF-RII, and streptavidin, all labeled with their respec-
tive fluorochromes, fixed, permeabilized, and run on a cy-
tometer (ImageStream X Mark II; Amnis). 50–100,000 event 
image files were automatically acquired using the Image-
Stream X (Amnis). Single-color controls were used to create a 
compensation matrix that was applied to all files to correct for 
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spectral overlap. The resulting compensated image files were 
analyzed using image-based algorithms available in the IDE 
AS statistical analysis software (version 6.2). Parameters were 
set to prevent the collection of small debris and dead cells.
Colocalization. Colocalization was assessed by comparing the 
small bright image detail of two fluorescent channels and thus 
calculating the BDS index of anti-TNF agent (red) and mem-
brane TNF (green) in CD14+ cell subsets or anti-TNF (red), 
TNF-RII (yellow), and membrane TNF (green) in the CD4+ 
T reg cell (pink)–CD14+(purple) conjugates. Colocalization 
was considered as a BDS of ≥1.75.
Intensity at the synapse valley mask. IDE AS identified a val-
ley mask, a region of contact between T reg cell–monocyte 
conjugates, before quantifying the expression intensity of anti- 
TNF, membrane TNF, or TNF-RII located within the mask.
Polarization. Delta Centroid values were calculated by IDE 
AS to determine the polarization index of TNF-RII distribu-
tion on the T reg cell surface.
STAT5 Phosflow
PBMCs were fixed with an equal volume of warm Phosflow 
Fix buffer I (BD) for 10 min at 37°C and then permeabilized 
for 10 min by cold Phosflow Perm/wash buffer III (BD) at 
4°C, followed by surface CD4 and CD14, intracellular Foxp3, 
and STAT5 staining. For some experiments, STAT5 inhibitor 
(N′[(4-oxo-4H-chromen-3-yl)methylene] nicotinohydrazide) 
was added to PBMCs for 1 h before adalimumab treatment.
Statistical analysis
Statistically significant differences were determined using 
Kruskal-Wallis or Friedman tests with Dunn’s post-hoc 
analysis using Prism software (GraphPad Software). P-val-
ues <0.05 were considered as statistically significant. 
P-values are denoted in figures as follows: *, P < 0.05; 
**, P < 0.01; ***, P < 0.001.
Online supplemental material
Fig. S1 describes the gating strategy for T reg cell 
purification and T reg cell depletion. Online supplemental 
material is available at http ://www .jem .org /cgi /content 
/full /jem .20151255 /DC1.
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Figure S1. Gating strategy for T reg cell purification and T reg cell depletion. (A) PBMCs were prepared for purification using flow cytometry after 
labeling with CD4, CD25, and CD127. Foxp3 staining was performed on a small aliquot before sorting. (B) The frequency of CD4+CD25+CD127− and 
CD4+FoxP3+ is shown after purification of T reg cells. (C) PBMCs were depleted of T reg cells, and the efficiency of depletion is shown based on staining 
with CD4, CD25, and CD127 (left) and CD4 and FoxP3 (right). Data are representative of at least four experimental repeats.
